These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 22526838

  • 1. A model of erythropoiesis in adults with sufficient iron availability.
    Fuertinger DH, Kappel F, Thijssen S, Levin NW, Kotanko P.
    J Math Biol; 2013 May; 66(6):1209-40. PubMed ID: 22526838
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [How do we optimally evaluate iron stores in dialyzed patients treated with erythropoiesis stimulating agent?].
    Kessler M, Salignac S, Aimone-Gastin I.
    Nephrol Ther; 2006 Sep; 2 Suppl 4():S261-5. PubMed ID: 17373268
    [Abstract] [Full Text] [Related]

  • 8. Hypoxic regulation of erythropoiesis and iron metabolism.
    Haase VH.
    Am J Physiol Renal Physiol; 2010 Jul; 299(1):F1-13. PubMed ID: 20444740
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The role of iron in erythropoiesis in the absence and presence of erythropoietin therapy.
    Goodnough LT.
    Nephrol Dial Transplant; 2002 Jul; 17 Suppl 5():14-8. PubMed ID: 12091601
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treating anemia with erythropoiesis-stimulating agents: effects on quality of life.
    Moossavi S, Freedman BI.
    Arch Intern Med; 2009 Jun 22; 169(12):1100-1. PubMed ID: 19546408
    [No Abstract] [Full Text] [Related]

  • 14. Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease.
    Barosi G, Merlo C, Palestra P, Liberato NL, Guarnone R, Di Dio F, Piazza V, Salvadeo A.
    Acta Haematol; 1993 Jun 22; 90(1):13-8. PubMed ID: 8237268
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Anemia therapy in ESRD: time to move on.
    Folkert VW, Meyer TW, Hostetter TH.
    Clin J Am Soc Nephrol; 2010 Jul 22; 5(7):1163-4. PubMed ID: 20538832
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evaluation of response to various erythropoiesis--stimulating proteins using anemia management software.
    Waterschoot M.
    J Ren Care; 2007 Jul 22; 33(2):78-82. PubMed ID: 17702511
    [Abstract] [Full Text] [Related]

  • 20. Hepcidin and regulation of iron homeostasis in maintenance hemodialysis patients.
    Sany D, Elsawy AE, Elshahawy Y.
    Saudi J Kidney Dis Transpl; 2014 Sep 22; 25(5):967-73. PubMed ID: 25193892
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.